Andrew W. Williams, Ph.D.

Partner
P: 312.913.3301
F: 312.913.0002

Andrew W. Williams is a partner with McDonnell Boehnen Hulbert & Berghoff LLP. Dr. Williams' practice primarily consists of patent litigation, prosecution, and opinion work in the areas of biotechnology, pharmaceuticals, and chemistry.

Published Articles

Dr. Williams is a contributing author to the Patent Docs weblog, a site focusing on biotechnology and pharmaceutical patent law.

"Biotechnology Patenting: What You Need to Know" BioLogical Quarterly, Winter/Spring 2010.

Memberships

American Association for the Advancement of Science
American Bar Association
American Intellectual Property Law Association
Chicago Bar Association

Distinctions

Extern, Hon. Richard Linn, U.S. Court of Appeals for the Federal Circuit

Publications

April 4, 2013 (snippets Alert)
The United States Patent and Trademark Office (“USPTO”) published its final rules in the April 3, 2013 Federal Register in preparation for adopting the new USPTO Rules of Professional Conduct (“USPTO Rules”). This is significant for any patent practitioner that has a USPTO registration number. Patent attorneys will no longer need to go back and forth between the old Model Code, as previously adopted by the Office, and the newer Model Rules, used by almost every jurisdiction in the U.S. However, Patent agents not accustomed to the ABA Model Rules will need to familiarize themselves with a completely new set of ethical obligations. We will highlight these changes in a future edition of snippets.

A number of comments were submitted when the USPTO first proposed these rules. One of the more contentious provisions involved the rules impacting the disclosure of confidential information, especially when that information belongs to a different client. The USPTO addressed these comments, and provided a potential solution should that ethical quandary occur. However, it did not change the proposed rules in response to these comments. This article provides an overview of these new rules, and describes the potential ethical quandary related to the disclosure of confidential information, and the USPTO’s response.
Summer 2004 (snippets)
Generate a PDF of your page(s)
Clear
Close
Remove
Page has been queued
An error has occurred
Add
Added to queue
View
Confirm Delete All Message
No Items in Packet Message
To add a page, select Add. To view the package, select View.
false
http://www.mbhb.com/professionals/xpqProfDetMBHB.aspx?xpST=ProfessionalDetail&professional=228&pdf=yes
a[href='javascript:packetBuilderSingleClick(document.title);']